PMID- 36601556
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230111
IS  - 2328-8957 (Print)
IS  - 2328-8957 (Electronic)
IS  - 2328-8957 (Linking)
VI  - 9
IP  - 12
DP  - 2022 Dec
TI  - Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant 
      Tuberculosis.
PG  - ofac500
LID - 10.1093/ofid/ofac500 [doi]
LID - ofac500
AB  - BACKGROUND: Linezolid has been prioritized for treating multidrug-resistant 
      tuberculosis (MDR TB), but toxicity limits its use. We report treatment outcomes 
      for MDR TB patients in California who received standard-dose linezolid vs those 
      who switched to low-dose. METHODS: We include culture-positive MDR TB cases 
      treated with linezolid and receiving California MDR TB Service consultation 
      during 2009-2016. Demographic, clinical, and laboratory data are analyzed using 
      univariate analysis to compare patients who received linezolid of different 
      dosing strategies. Analysis end points are linezolid treatment duration (measure 
      of tolerability), treatment success (completion or cure), and adverse events 
      (AEs). RESULTS: Sixty-nine of 194 (36%) MDR TB patients met inclusion criteria. 
      While all patients began linezolid treatment at 600 mg daily, 39 (57%) continued 
      at this dosage (standard-dose), and 30 (43%) switched to 300 mg daily (29%) or 
      intermittent dosing (14%) (low dose). Patients on standard-dose linezolid were 
      treated for 240 days, compared with 535 for those on low-dose (P < .0001). 
      Sixty-three patients (91%) achieved treatment success, 2 (2.9%) died, 1 (1.5%) 
      failed treatment, 1 (1.5%) stopped treatment due to side effects, and 2 (2.9%) 
      were lost or moved. Treatment success was higher (P = .03) in the low-dose group. 
      Sixty-two patients experienced >/=1 hematologic (71%) or neurologic (65%) AE. Those 
      on low-dose linezolid experienced significantly (P = .03) fewer AEs per 
      linezolid-month after switching (0.32 vs 0.10). CONCLUSIONS: Patients who 
      switched to low dose tolerated linezolid longer with better treatment outcomes 
      and fewer recurring AEs.
CI  - (c) The Author(s) 2022. Published by Oxford University Press on behalf of 
      Infectious Diseases Society of America.
FAU - Mase, Anjeli
AU  - Mase A
AUID- ORCID: 0000-0002-5392-2506
AD  - Division of Hematology/Oncology, University of California, San Francisco, 
      California, USA.
FAU - Lowenthal, Phil
AU  - Lowenthal P
AD  - California Department of Public Health Tuberculosis Control Branch, Richmond, 
      California, USA.
FAU - True, Lisa
AU  - True L
AD  - California Department of Public Health Tuberculosis Control Branch, Richmond, 
      California, USA.
FAU - Henry, Leslie
AU  - Henry L
AD  - California Department of Public Health Tuberculosis Control Branch, Richmond, 
      California, USA.
FAU - Barry, Pennan
AU  - Barry P
AUID- ORCID: 0000-0003-2962-1890
AD  - California Department of Public Health Tuberculosis Control Branch, Richmond, 
      California, USA.
FAU - Flood, Jennifer
AU  - Flood J
AD  - California Department of Public Health Tuberculosis Control Branch, Richmond, 
      California, USA.
LA  - eng
PT  - Journal Article
DEP - 20221005
PL  - United States
TA  - Open Forum Infect Dis
JT  - Open forum infectious diseases
JID - 101637045
PMC - PMC9801093
OTO - NOTNLM
OT  - linezolid
OT  - low-dose
OT  - multidrug-resistant
OT  - treatment
OT  - tuberculosis
COIS- Potential conflicts of interest. The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper. All authors have submitted the 
      ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the 
      editors consider relevant to the content of the manuscript have been disclosed.
EDAT- 2023/01/06 06:00
MHDA- 2023/01/06 06:01
PMCR- 2022/10/05
CRDT- 2023/01/05 02:35
PHST- 2022/08/11 00:00 [received]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2023/01/05 02:35 [entrez]
PHST- 2023/01/06 06:00 [pubmed]
PHST- 2023/01/06 06:01 [medline]
PHST- 2022/10/05 00:00 [pmc-release]
AID - ofac500 [pii]
AID - 10.1093/ofid/ofac500 [doi]
PST - epublish
SO  - Open Forum Infect Dis. 2022 Oct 5;9(12):ofac500. doi: 10.1093/ofid/ofac500. 
      eCollection 2022 Dec.